Industry: Healthcare

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. ERYTECH Pharma S.A. has research collaboration with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is headquartered in Lyon, France.

Current Quote*
Last: $6.420
Change: 0.010
Book: $0.623
Volume: 502

As Of: 02/21 13:00 ET
*Quotes delayed by 20min.

Graphs for ERYP

3 Month Graph

6 Month Graph

1 Year Graph